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Takotsubo cardiomyopathy (TTC), also known as 
stress-induced cardiomyopathy, is a condition 
with left ventricular (LV) dysfunction, most 
commonly apical ballooning and less frequently 
Abstract 
Takotsubo cardiomyopathy, also referred to as stress-induced cardiomyopathy, is an acute condition 
associated with transient left ventricular dysfunction. Since it can be induced by increased emotional stress 
(such as losing a loved one or constant anxiety) it is also called the broken heart syndrome. This type of 
cardiomyopathy occurs in all age groups and both sexes, but it is most common in postmenopausal women. 
There are several clinical manifestations such as chest pain, sometimes with heart failure, and often with ST-
segment changes that may present as acute coronary syndrome. It is characterized by absence of coronary 
artery obstruction, with transient regional wall motion abnormalities and minimal elevation of cardiac enzyme 
levels. Although wall motion abnormalities are reversible in almost all cases, and long-term prognosis is 
excellent, this condition is important because in the acute phase it may cause sudden cardiac death. 
Mechanisms and cause of this disease still remain unclear. Some possible causes of the disorder include: 1) 
coronary artery vasospasm, 2) microcirculatory dysfunction, 3) transient obstruction of the left ventricular 
outflow tract, and 4) excessive release of catecholamine, which seems to have the most important role. The 
aim of this review is to summarize the most important pathophysiological mechanisms that may be responsible 
for the development of this type of cardiomyopathy. 
(Mlinarevic D, Roguljic H, Juric I, Zebic Mihic P, Ivandic M, Stupin M. Pathophysiological Mechanisms of 
Takotsubo Cardiomyopathy - a Systematic Review. SEEMEDJ 2017;1(1);27-39) 
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midventricular or basal dysfunction. It was first 
described by Sato et al. in the early 1990s, who 
named it Takotsubo because the appearance of 
the LV is reminiscent of the octopus trap (1). The 
exact cause of this disease is still unclear. TTC 
clinically manifests with sudden chest pain and 
dyspnea preceded by emotional or physical 
stress, which are similar to those in acute 
coronary syndrome (ACS). Besides the onset of 
chest pain, ST-segment elevation and increase 
in creatine kinase and troponin are very 
common, and it is necessary to exclude 
obstructive coronary artery disease (CAD) (2).  
Different types of LV wall motion abnormalities 
have been reported – apical, mid-ventricular or 
basal hypokinesia, dyskinesia or akinesia. Beside 
the LV, right ventricle may also be affected and 
it is associated with more severe LV dysfunction 
(3). Any form of dysfunction is reversible with 
resolution achieved in several days or weeks. 
Overall prognosis is favorable, but acute phase 
can be accompanied with acute heart failure and 
cardiogenic shock, rupture of the LV, malignant 
arrhythmias and in worst cases sudden cardiac 
death (4). For TTC diagnosis, four diagnostic 
criteria are suggested: 1) new electrocardiogram 
(ECG) abnormalities (convex ST-segment 
elevation); 2) transient apical dyskinesia or 
akinesia detected by echocardiography (ECHO); 
3) non-obstructive CAD at angiography: 4) 
absence of myocarditis, pheochromocytoma, 
head trauma and intracranial hemorrhage or 
hypertrophic cardiomyopathy (5). 
The actual incidence of TTC is unknown, but it is 
considered that prevalence among patients with 
ACS symptoms is 0.7-2.5%, and it is found most 
commonly in postmenopausal women (6). Since 
no large studies have confirmed the etiology of 
stress cardiomyopathy, determination of 
underlying cause is not possible, but it is almost 
always preceded by exaggerated emotional, 
physical or mental stress. Sudden death of a 
loved one, traffic accidents, various types of 
abuse, business failure, endoscopy, sexual 
intercourse and other are described as potential 
triggers of TTC. So far, several possible 
pathological mechanisms have been proposed, 
including coronary artery vasospasm, coronary 
microcirculatory dysfunction, myocarditis, 
obstruction of the left ventricular outflow tract 
(LVOT), abnormal metabolism of free fatty acids 
in the cardiac apex and catecholamine overload 
(7). TTC does not require specific treatment; 
management is primarily empirical and needs to 
be individualized for each patient (8).  
This review will explain recent findings about the 
pathophysiological mechanisms in this type of 
cardiomyopathy. 
Clinical Presentation, Diagnosis and 
Prognosis 
Since TTC patients present with chest pain, 
dyspnea and syncope, it is difficult to 
differentiate it from ACS based on ECG and 
laboratory findings. Last findings suggest that 
approximately 1-2 % of patients presenting as 
ACS are ultimately identified as TTC (3, 9). There 
is no age group or sex that cannot be affected, 
but there is female predominance (more than 
80% of patients are postmenopausal women) 
and it affects older adults more frequently (10-
16). Similar to ACS, TTC patients also have 
cardiovascular comorbidities such as smoking, 
hypertension and dyslipidemia (17). 
TTC is often, but not always, triggered by 
emotional or physical stress such as receiving 
bad news, unexpected death of relatives, 
dissatisfaction with relationships, devastating 
financial loss or acute medical illness. Some of 
the physical stressors include major surgeries 
like trauma surgery, infections or neurologic 
conditions. Patients with psychiatric or 
neurologic disorders may be predisposed to 
stress cardiomyopathy. Virtually any stressor, 
evena minor one, can be a precipitant of stress 
cardiomyopathy. It is worth mentioning that no 
stressor is identified in up to one-third of 
patients.  
Physical findings are nonspecific and often 
normal, but the patient may present with signs 
of ACS or acute congestive heart failure. Other 
symptoms include nausea, vomiting and 
palpitations.  Cardiac bradyarrhythmias and 
tachyarrhythmias, including ventricular 
tachycardia and ventricular fibrillation, may 
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develop. (10, 11, 18-20). Some patients may 
develop signs of heart failure, and 
approximately 10% of patients may develop 
cardiogenic shock (21-23). Left ventricular 
outflow tract obstruction caused by left 
ventricular basal hyperkinesis produces late-
peaking systolic murmur and can contribute to 
severe mitral regurgitation, hypotension and 
shock (24). 
Like any patient in whom ACS is suspected, ECG 
should be the initial test obtained. ECG 
abnormalities are common in patients with TTC 
(25). Most common abnormalities on initial ECG 
are ST-segment elevation and T-wave inversion. 
Studies found that ST-segment elevations 
involve the precordial leads and are maximal in 
leads V2-V3 (26). Patients with TTC have a 
significantly lower amplitude of ST segment 
elevation compared to STEMI from LAD 
occlusion. ST depression is a less common 
finding in patients with TTC. Kosuge et al. found 
that combination of absent abnormal Q waves, 
absent reciprocal changes, lack of ST-segment 
elevation in lead V1, and the presence of ST-
segment elevation in lead aVR had 91% 
sensitivity and 96% specificity for TTC. Other 
possible findings include QT interval 
prolongation and non-specific ECG 
abnormalities. However, all these criteria have 
imperfect diagnostic accuracy and are not 
reliable for differentiation between the two 
conditions in the emergency setting to guide 
their management (e.g. decision to undergo 
emergency coronary angiography) (27). 
Serum cardiac troponin I levels (TnI) are elevated 
in 90% of patients with TTC, while creatine kinase 
levels are generally normal or slightly elevated. 
The brain natriuretic peptide (BNP) orN-terminal 
pro-BNP are elevated in most patients with TTC 
(25). In patients with TTC, mean TnI level at the 
time of admission has been reported as 
moderately elevated. Nascimento et al. used 
this finding to create a criterion for differentiating 
between STEMI and TTC (28). The troponin 
ejection fraction product (TEFP) is the product of 
the peak troponin I level and the 
echocardiographically acquired ejection 
fraction. A TEFP ≥250 had an overall accuracy of 
91% for STEMI identification. Budnik et al. found 
that the NTproBNP / TnI ratio was capable of 
distinguishing between TTC and STEMI. In this 
study, the concentration of NTproBNP was 
greater in patients with TTC than in ones with 
STEMI, while the concentration of TnI and CKMB 
mass was higher in the STEMI group than in the 
TTC group (29). Several studies analyzed the 
levels of circulating catecholamines in the acute 
phase and found that 75% of TTC patients had 
higher levels than patients with STEMI, but their 
role in diagnosing TTC is unclear (30,31). 
Wall motion abnormalities are best identified by 
echocardiography or left ventriculography. 
Trans-thoracic echocardiography (TTE) is used 
as a quick method of diagnosing wall-motion 
abnormalities typical for TCC (32), such as 
hypokinesis or akinesis of the mid-segment and 
apical segment of the LV, which is present in 
81.7% of patients (25). Crucially, these wall-
motion abnormalities extend beyond the 
distribution of any single coronary artery. LV 
ejection fraction was found to be 20-49% on 
admission. The resolution of TTC usually occurs 
within four weeks with LVEF improving to 59-
76%. 
TTC diagnosis is usually confirmed by coronary 
angiography. Acute presentation with ST-
segment elevation and symptoms suggestive of 
ACS mandate immediate evaluation with 
coronary angiography to exclude coronary 
occlusion.  
The prognosis in TCM is excellent in most cases, 
with nearly 95% of patients experiencing 
complete recovery within 4-8 weeks (13). 
Mortality estimates range from 1% to 5.9%. 
Complications occur in around 20% of patients 
and include LV outflow obstruction, heart failure, 
ventricular arrhythmias, mitral regurgitation, LV 
mural thrombus formation or death. International 
Takotsubo Registry reported 5.9% mortality after 
30 days (33). The rate of mortality during long-
term follow-up was 5.6% per patient-year. A 
Swedish registry study found a 30-day mortality 
of 4.1% in 302 patients with TTC (34). These trials 
compared mortality in TTC with matched 
cohorts of patients with acute myocardial 
infarction or acute coronary syndrome and 
found a similar risk of death. 
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Coronary vasospasm and 
microcirculatory dysfunction 
Coronary vasospasm was the first 
pathophysiological process considered as a 
cause TTC in the original article by Sato et al. in 
1991 (35). Since TTC usually presents with 
transient wall motion abnormalities (“stunned 
myocardium”) covering the irrigation territories 
of several coronary arteries (36), a multivessel 
coronary vasospasm could be the potential 
cause. However, according to current literature, 
coronary vasospasm is not a likely cause, 
because spontaneous vasospasm is rare in 
these patients (37) and cannot be induced in all 
the patients during angiography (38). Finally, TTC 
has a specific histological phenotype which 
differs from stunning associated with coronary 
artery disease (39). 
On the other hand, there is an increasing body of 
evidence that microvascular dysfunction is one 
of potential pathophysiological mechanisms of 
disease. Diffuse microcirculatory dysfunction 
could explain wall motion abnormalities (WMAs) 
in several myocardial regions. Microcirculatory 
dysfunction may be primary or secondary, i.e. 
caused by excess of circulating cateholamines 
(37). The consequence of microcirculatory 
dysfunction is coronary slow flow (CSF), which in 
turn causes myocardial WMAs (40). Several 
methods have been used for evaluating CSF – 
Doppler guidewire during angiography (41), TIMI 
(Thrombolysis in myocardial infarction) 
myocardial perfusion grade (TMPG) (42, 43) and 
TIMI frame count (TFC) (11,44). The most 
commonly used method is TFC which is defined 
as “the number of frames required for the 
contrast material to travel from coronary ostium 
to the standardized distal landmark” (44). Several 
studies have demonstrated an increased TFC 
(i.e. slower coronary flow) in TTC patients (45-47), 
which supports the role of microcirculatory 
dysfunction. A study by Martin et al. in 2013, 
using peripheral arterial tonometry, 
demonstrated increased vascular reactivity and 
decreased endothelial function in response to 
acute mental stress in patients with previous 
TTC (48).  
Although most of the available literature 
supports the role of either primary or secondary 
microcirculatory dysfunction in TTC, it is 
important to acknowledge that the results are 
not always uniform. A recent retrospective study 
by Khalid et al. found the TFC to be higher in left 
anterior descending (LAD) coronary artery of 
TTC patients, but no difference was found in TFC 
in right (RCA) or circumflex (CX) coronary artery 
(45). This anatomical distribution could explain 
the most common form of TTC involving the 
apex and the midventricular subtype, but not the 
less frequent form which involves the basal 
myocardium. Sharkey et al., in 2008, found a 
modest increase in TFC in TTC patients 
compared to controls (acute anterior STEMI with 
LAD occlusion), which was statistically 
significant in LAD and CX, but not in the RCA (30). 
Abe et al. (2003) found no coronary slow flow, no 
abnormalities using Doppler guidewire 
technique and no evidence of viral myocarditis 
in a series of 17 patients (49). Collste et al. (2015) 
investigated coronary flow reserve (CFR) by 
dobutamine stress echocardiography and the 
authors could not induce microcirculatory 
dysfunction, but found CFR at low-dose 
dobutamine was significantly lower in patients 
with TSC compared to controls (50). 
Metabolic Disturbance 
One possible hypothesis is that TTC may be 
considered a metabolic form of cardiomyopathy 
with disturbed cardiomyocyte metabolism. 
Several studies that were researching metabolic 
changes in stunned myocardium found 
alterations in glucose and fatty acid uptake. 
Those alterations may be the result of primary 
metabolic disturbance in cardiomyocyte or due 
to mitochondrial disturbance (51, 52). The 
metabolic disturbance was likely linked to the 
sudden preceding stress and resulted in 
corresponding perfusion abnormalities. 
Yoshida et al. describe abnormalities in coronary 
perfusion and severe myocardial metabolic 
disorder in patients with TTC based on the 
results of thallium-201 myocardial single-photon 
emission computed tomography (SPECT) and F-
18 fluorodeoxyglucose (F-18 FDG) myocardial 
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positron emission tomography (PET). They 
noticed markedly decreased uptake of F-18 
FDGon PET at the apical region while thallium 
201 images showed only mildly reduced uptake. 
Reason for decreased uptake may be due to 
increased density of beta receptors noted in 
apex (53).Several studies have reported 
prolonged reduction and reduced uptake of F-
18 FDG in patients subjected to multiple cycles 
of ischemia and reperfusion (54, 55). Still, the 
precise mechanism for reduced glucose uptake 
in stunned myocardium remains unknown. 
LVOT obstruction & Myocarditis 
According to earlier studies, LVOT obstruction is 
registered in 15-25% of patients with TTC (10, 56) 
and Kawaji et al detected it in 33% of patients 
(57). Although it was proposed as a possible 
pathophysiological mechanism of the disease, it 
remains uncertain whether it is a consequence 
rather than a cause of stress cardiomyopathy 
(37, 58).  
Some researchers claim that there is much 
evidence indicating this relation actually exists. 
Transient dynamic LVOT gradient was detected 
at initial evaluation in a substantial proportion of 
patients described by Tsuchihashi et al. (1) and 
other investigators (24, 59). At least in some 
patients, a possible mechanism for TTC could be 
a dynamic LVOT obstruction preceding the 
ischemic event. Some of those patients, 
primarily women, may have geometric 
predisposition to dynamic LVOT obstruction, 
such as sigmoid or bulging interventricular 
septum (60, 61), reduced left ventricular volume 
(62-64) or abnormal mitro-aortic and septo-
aortic angles (65), which may manifest only in 
the setting of intense adrenergic stimulation or 
hypovolemia (37). Elderly women have a higher 
tendency to develop hypertrophy of the basal 
anterior septum. The angle of the septum may 
cause increase in the speed in the outflow tract 
which simulate a hypertrophic cardiomyopathy 
(66). It is also associated with an abnormal 
orientation of the mitral valve due to flaccidity, 
deformity of valve, false chordae, disturbances 
of the papillary muscles, or systolic anterior 
movement (67-69) with mitral regurgitation. It is 
known that even in a normal heart, exposure to 
an exogenous catecholamine, such as 
dobutamine infusion, can precipitate dynamic 
LVOT obstruction (70).  
If present, the dynamic obstruction increases 
apical LV wall stress and LV filling pressure, 
increasing myocardial oxygen demand at the 
mid-to-apical cavity. If this persists, apical 
hypoperfusion and ischemia may occur, with 
regional wall motion abnormality and stunning. 
Increased adrenergic tone might produce 
primary LVOT obstruction leading to secondary 
ischemia and focal wall-motion abnormalities. 
Physical or emotional stress could be the trigger 
of acute development of LVOT obstruction, 
which could produce severe apical ischemia. 
Identification of acute dynamic LVOT 
obstruction as the possible initial mechanism in 
some of the patients with stress cardiomyopathy 
may have important clinical and therapeutic 
implications (71). 
Previously suggested possible role of a transient 
dynamic LVOT obstruction in the pathogenesis 
of this syndrome is not strongly supported by 
other investigators. According to Ishihara, it is 
unlikely that LVOT obstruction is the cause of 
TTC because most of these patients do not have 
LVOT obstruction. It is known that this condition 
is characterized not only by reduced apical LV 
wall motion, but also hyperkinesis of the basal 
LV wall, and that the combination possibly 
causes the LVOT obstruction (57, 72, 73). LVOT 
obstruction is not a prerequisite, but can 
contribute in a deteriorating clinical course of 
TTC (71, 73). 
Takotsubo cardiomyopathy is characterized not 
only by reduced apical LV wall motion, but also 
hyperkinesis of the basal LV wall. This 
combination causes the LVOT obstruction in 
TTC.  
The suggested possibility that myocarditis leads 
to transient LV dysfunction and Takotsubo 
cardiomyopathy is not well supported by the 
data. Arguments to rule out myocarditis include 
absence of typical clinical signs, unspecific 
findings on myocardial biopsy and negative 
results on serum tests for viral serology. Some 
studies used cardiac magnetic resonance 
SEEMEDJ 2017, VOL 1, NO. 1 Implementation of the N - terminal proB-type natriuretic peptide test… 
 
32 Southeastern European Medical Journal, Vol 1, 2017. 
 
imaging, which has shown no evidence of 
myocarditis (35, 74-77). 
Catecholamines – pathophysiological 
hallmark of stress cardiomyopathy 
Exposure to high intensity stress conditions, 
whether physical or emotional, has been 
associated with most cases of TTC (37). 
Furthermore, patients with pheochromocytoma, 
a catecholamine-producing tumor, are prone to 
develop a similar form of cardiomyopathy (78). In 
the animal model of subarachnoid hemorrhage, 
a condition with heightened catecholamine 
levels, a correlation between the extent of 
myocardial damage and sympathetic discharge 
was reported (79). Those observations suggest 
increased sympathetic activity and 
catecholamine mediated effect as a crucial 
factor for development of the broken heart 
syndrome. Although apart from catecholamine-
mediated effect other theories about 
pathophysiology of stress cardiomyopathy 
coexist, the current Mayo Clinic criteria require 
catecholamine-producing tumor to be ruled out 
for establishing a TTC diagnosis (80).   
Relationship between high levels of serum 
catecholamines and stress in patients suffering 
from cardiomyopathy was first shown in 2003 
(76). Abraham et al. reported the emergence of 
all morphologic forms of TTC in patients 
exposed to catecholamines and other beta-
receptor agonists used routinely during 
procedures and diagnostic tests (81). Study of 
Wittstein et al. reported that levels of 
catecholamines and dopamine are 
approximately two to three times higher in 
patients with TTC in comparison with 
cardiomyopathy caused by acute myocardial 
infarction (77). Interestingly, the correlation 
between morphological changes of the left 
ventricle in TTC and distribution of 
adrenoreceptors has been observed. A majority 
of β2 receptors with negative inotropic effect is 
in the apex of the left ventricle where ballooning 
process takes place which is consistent with a 
theory of catecholaminergic stress (39). 
Moreover, increased release of the 
catecholamines from the hearts of the patients 
affected with TTC has been reported (82). Some 
of the nuclear imaging studies also stressed the 
influence of the sympathetic nervous system in 
development of TTC. In eight patients with TTC, 
a decreased 123i-metaiodobenzylguanidine 
uptake within left ventricle was registered, 
indicating the existence of cardiac sympathetic 
hyperactivity as pathophysiological pathway 
(83). Moreover, a concordance between regional 
wall motion abnormalities and reduced uptake 
of the glucose and free fatty acid has been 
shown (84). Although this impairment of 
metabolism is not fully understood, 
catecholamine induced injury of 
cardiomyocytes is probably the cause of a 
metabolic stunned myocardium. Experiments in 
animals provided further evidence regarding the 
role of the catecholamines in disease patho-
genesis. Iatrogenic administration of β2 
agonists or immobilization stress in animals can 
result in reversible left ventricular apical 
ballooning. This adverse effect could be 
mitigated by α- and β-receptor blocking 
agents (85, 86). 
Stress cardiomyopathy is characterized by 
similar molecular manifestations as the other 
catecholamine-mediated cardiomyopathies. 
Those morphological alterations caused by 
catecholamine overload include: extracellular 
matrix overproduction, contraction band 
necrosis and mononuclear cell infiltration (37). 
Catecholamine induced accumulation of 
collagen α-1 (I) chain in extracellular matrix 
results in large and rapid increase in fibrosis. 
High levels of catecholamine may result in high 
levels of profibrotic mediators (angiotensin II and 
free oxygen radicals), which can activate 
stimulating connective tissue growth factor, 
transforming growth factor β and the profibrotic 
osteopontin (87). Catecholamine overload 
stimulates β-adrenoreceptors and alters the 
expression of calcium-regulatory protein genes 
which cause alteration of the calcium regulatory 
system (88). Sarcolipin (SLN) and 
Phospholamban (PLN) are proteins of 
sarcoplasmic reticulum (SR) which regulate 
cardiac contractility. SLN regulates the 
sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2 (SERCA2) by lowering its affinity for 
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calcium. In acute phase of TTC, ventricular 
expression of SLN is raised and could contribute 
to contractile dysfunction (89). 
At physiological conditions, binding nore-
pinephrine on β1 – adrenoreceptors (β1AR) and 
epinephrine on β2 adrenoreceptors (β2AR) in 
cardiomyocytes results in positive inotropic 
response. In normal human ventricular 
myocardium, there are four times more β1AR 
than β2AR (90). Positive inotropic response is 
the result of β1AR or β2AR activating 
stimulatory G protein (Gs) family, which activates 
protein kinase A (PKA) pathway reflected as an 
increased contractile response (91).  
Supraphysiological levels of catecholamines 
result in β2-coupling from Gs to inhibitory G 
protein (Gi), which is reflected as a negative 
inotropic effect. This process is also called 
stimulus trafficking (92). The density of β2AR is 
the highest in cardial apex, so there is the 
greatest negative inotropic effect (91). The β2AR 
-Gi protein pathway can activate the p38 
mitogen-activated protein kinase (MAPK) 
alteration of myofilament sensitivity. β2AR–Gi 
protein has a favorable outcome on stress 
cardiomioypathy by stimulating the Pi3K–aKt-
signaling pathway, which activates antiapoptotic 
genes (NFκB1 and BCL2) (37). This is a 
physiological balance because β1AR–Gs 
protein pathway has the proapoptotic effect (93). 
It is cardioprotective because it minimalizes 
catecholaminergic stimulation. After 
epinephrine levels are normalized, β2AR–Gi 
switch to β2AR–Gs or are degraded, which 
results in recovery of cardiomyocyte contractile 
function (91).  
Figure 1. Schematic overview of pathophysiological mechanisms involved in catecholamine-mediated Takotsubo cardiomyopathy. 
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Although pathophysiological pathway of TTC is 
still unclear, it is certain that catecholamine 
overload presents a common denominator in 
development of the broken heart syndrome, as 
presented in Figure 1. Despite plentiful clinical 
findings, further research is obligatory to 
complete the puzzle of this rare but potentially 
severe disease. 
Conclusion 
Takotsubo cardiomyopathy is an important type 
of acute heart failure with transient left 
ventricular wall motion abnormalities. The 
symptomatology, echocardiographic and 
electrocardiographic features frequently mimic 
acute coronary syndrome, which is why TTC 
must be considered in a differential diagnosis of 
patients with acute chest pain. According to 
contemporary literature, TTC is most likely 
caused by supraphysiological levels of 
catecholamines due to acute mental stress. 
Elevated catecholamine levels induce 
myocardial fibrosis, and contractile and 
microvascular dysfunction. While the 
manifestation of TTC can be clinically dramatic 
and potentially life-threatening, the prognosis is 
usually excellent – 95% of patients fully recover 
within one to two months.  
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